Developing stable cell lines is one of the most critical, yet time-consuming, steps in recombinant therapeutic protein development. This article explores how improving the quality of the starting cell pool can streamline stable cell line development, accelerate early workflows, and help reduce the resources required to identify high-performing production clones.
You may also be interested in:
Expression Technologies
Bispecific Antibody
Monoclonal Antibody
Cell Line Development
Author(s):
Peter O'Callaghan, Ph.D.
Head of Expression System Sciences
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.
Latest briefing from the Knowledge Center
Article
Streamlining Stable Cell Line Development from the Start
Developing stable cell lines is one of the most critical, yet time-consuming, steps in recombinant...
White paper
Characterizing Extracellular Vesicles Across Analytical and Process Development
As extracellular vesicle (EV) therapeutics progress toward clinical and commercial applications,...
Article
Could your Microbial Process be Stronger? Uncovering Opportunities Before Scale-up and...
As microbial products advance toward later clinical phases and commercialization, process...
Webinar (on-demand)
Before IND, Know: How to Overcome Early Development Challenges Before They Impact Your Program
In this on-demand webinar, Dr. Yvette Stallwood, Head of Early Development Services, shares...
CDMO Notes Blog post
How Early Immunogenicity Insights Can Change Bispecific Candidate Selection
When selecting a bispecific candidate, strong potency or binding data may not tell the whole story....
CDMO Notes Blog post
Scaling with Confidence: Why Resilient Upstream Operations Matter for Tech Transfer Success
From engineering runs to GMP execution, learn how manufacturing teams help transform technology...
Poster
GS Ori-Go®: Next-Generation CHO Expression Vectors for Enhanced Productivity, Stability and Speed
Lonza is advancing its leading GS Gene Expression System® with the next-generation GS Ori-Go® vector...
Article
Manufacturability and Developability Assessment as the Technical Foundation of a Strong Biologic...
In this article, our expert Michael Hodskinson, Ph.D., discusses why manufacturability and...
Article
Early Protein Expression Assessment and the Value of Starting in a Proven System
In this article our experts discuss the role of early protein expression assessment as a critical...
White paper
Overcoming the Obstacles of Spray-Dried Dispersion Scale-Up
As poorly soluble small-molecule drug candidates continue to challenge development timelines, the...
Article
Early-Stage Biotech Success Starts with the Right Development and Manufacturing Partner
Article
The Specifics of Speed: How to Reach the Clinic Faster While Maintaining Precision
How can mAb programs reach the clinic in as little as six months without increasing CMC risk? Are...